Figure 2.
Percentage of circulating immune cells from patients with COVID-19 and unexposed individuals, at different stages of the disease. (A) Gate strategy accessing the subpopulation of PBMCs by ex vivo immunophenotyping. (B) Percentage of total NK cells, (C) total monocytes, (D) total CD4+ T cells, and (E) total CD8+ T cells, obtained from unexposed individuals and patient with COVID-19. Percentage of obtained from unexposed individuals and patients with COVID-19 (**p < 0.01, and ****p < 0.0001).